Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | KDM1A | O60341 | 4/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | FNTA | P49354 | 4/20 | 0.56 |
| ▸ | FNTB | P49356 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8568308 | 0.86 | HDAC6 (0.56) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL13722157 | 0.85 | MAPT (0.66) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL17356858 | 0.81 | MAPT (0.51) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL7280026 | 0.80 | NPSR1 (0.62) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL31014072 | 0.80 | MEN1 (1.00) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL179882 | 0.80 | MEN1 (1.00) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL18883324 | 0.79 | NOTUM (0.54) | MAPTMEN1KMT2AALDH1A1KDM1A | |
| SCHEMBL13722563 | 0.79 | MEN1 (0.73) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL6542868 | 0.79 | MEN1 (0.73) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL13722057 | 0.79 | MAPT (0.61) | MAPTMEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020119136-A1 | Antimicrobial peroxidase compositions | NOVOZYMES A/S (DK) | 2002-08-29 | — | — | US | claimed |
| CN-115612114-B | Copolymer membrane and method for enzymatic self-assembly synthesis and application thereof | 中国科学院天津工业生物技术研究所 | 2024-02-20 | — | — | CN | disclosed |
| CN-115612403-B | Self-assembled strong-adhesion copolymer film, coating method and application | 中国科学院天津工业生物技术研究所 | 2023-12-01 | — | — | CN | disclosed |
| EP-3625316-B1 | DISPERSANTS, METHOD OF MAKING, AND USING SAME | CHEVRON ORONITE CO (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-110621766-B | Dispersant, method of manufacture and use thereof | 雪佛龙奥伦耐有限责任公司 | 2021-12-24 | — | — | CN | disclosed |
| US-10815446-B2 | Dispersants, method of making, and using same | CHEVRON ORONITE COMPANY LLC (US) | 2020-10-27 | — | — | US | disclosed |
| CN-110621766-A | Dispersant, method of manufacture and use thereof | 雪佛龙奥伦耐有限责任公司 | 2019-12-27 | — | — | CN | disclosed |
| US-20180334635-A1 | DISPERSANTS, METHOD OF MAKING, AND USING SAME | CHEVRON ORONITE COMPANY LLC | 2018-11-22 | — | — | US | disclosed |
| US-6660503-B2 | In aqueous solution | NOVOZYMES A/S (DK) | 2003-12-09 | — | — | US | disclosed |
| EP-0935692-B1 | FABRIC TREATED WITH CELLULASE AND OXIDOREDUCTASE | NOVOZYMES AS (DK) | 2002-11-27 | — | — | EP | disclosed |
| WO-1996006930-A1 | COPRINACEAE LACCASES | NOVO NORDISK A/S (DK) | 1996-03-07 | — | — | WO | disclosed |
| WO-1996005837-A1 | USE OF N-SUBSTITUTED PHENOTHIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-02-29 | — | — | WO | disclosed |
| US-5445755-A | Containing hydrogen peroxide source, phenothiazine or phenoxazine peroxidase accelerator; inhibit dye transfer | THE PROCTER & GAMBLE COMPANY (US) | 1995-08-29 | — | — | US | disclosed |
| US-4225617-A | PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1980-09-30 | — | — | US | disclosed |
| US-4209524-A | CENTRAL NERVOUS SYSTEM | LABORATOIRE L. LAFON (FR) | 1980-06-24 | — | — | US | disclosed |
| US-4209523-A | TREATMENT OF THE CENTRAL NERVOUS SYSTEM | LABORATOIRE L. LAFON (FR) | 1980-06-24 | — | — | US | disclosed |
| US-4183951-A | PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1980-01-15 | — | — | US | disclosed |
| US-4152458-A | CENTRAL NERVOUS SYSTEM, PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1979-05-01 | — | — | US | disclosed |
| US-4151300-A | CENTRAL NERVOUS SYSTEM, PSYCHOTROPIC | LABORATOIRE L. LAFON (FR) | 1979-04-24 | — | — | US | disclosed |
| US-4122186-A | PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1978-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119136-A1 | Antimicrobial peroxidase compositions | LPO, MPO, GPX4 | MAPT 4153/4885MEN1 4044/4885KMT2A 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.